Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Kang, Tae Heung ^a   Mao, Chih Ping ^a   He, Liangmei ^a   Tsai, Ya Chea ^a   Liu, Katherine ^a   La, Victor ^a   Wu, T C ^a,b   Hung, Chien Fu ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 2; LUCIFERASE; NATURAL KILLER CELL RECEPTOR NKG2D; WART VIRUS VACCINE; FC RECEPTOR; HYBRID PROTEIN; KLRK1 PROTEIN, MOUSE; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CD8+ T LYMPHOCYTE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; ELECTROPORATION; FEMALE; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; OVARY TUMOR;

HUMAN PAPILLOMAVIRUS; MUS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-2; LIGANDS; LUCIFERASES; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OVARIAN NEOPLASMS; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

EID: 84859575285     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035141     Document Type: Article

References (29)

1. Utreja P, Jain S, Tiwary AK, (2010) Novel drug delivery systems for sustained and targeted delivery of anti- cancer drugs: current status and future prospects. Curr Drug Deliv 7: 152-161.
2. Ertl HCJ, Zaia J, Rosenberg SA, June CH, Dotti G, et al. (2011) Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010. Cancer research 71: 3175-3181.
3. Pulé MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, et al. (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy 12: 933-941.
4. Ramos CA, Dotti G, (2011) Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opinion on Biological Therapy 11: 855-873.
5. Waldmann TA, (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
6. Malek TR, Bayer AL, (2004) Tolerance, not immunity, crucially depends on IL-2. Nature Reviews Immunology 4: 665-674.
7. Vella AT, Dow S, Potter TA, Kappler J, Marrack P, (1998) Cytokine-induced survival of activated T cells in vitro and in vivo. Proceedings of the National Academy of Sciences 95: 3810-3815.
8. Ma A, Koka R, Burkett P, (2006) Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24: 657-679.
9. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine 316: 889-897.
10. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, et al. (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Annals of Surgery 210: 474-485.
11. Raulet DH, (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790.
12. Nausch N, Cerwenka A, (2008) NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
13. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, et al. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
14. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, et al. (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21: 585-591.
15. Kim D, Hung CF, Wu TC, (2007) Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther 18: 575-588.
16. Lin CT, Tsai YC, He L, Yeh CN, Chang TC, et al. (2007) DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunology letters 114: 86-93.
17. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, et al. (2000) Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042.
18. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, et al. (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27: 5450-5459.
19. Lee CF, Chang SY, Hsieh DS, Yu DS, (2004) Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. Cancer Gene Ther 11: 194-207.
20. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO, (2005) Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11: 435-443.
21. Zhang T, Lemoi BA, Sentman CL, (2005) Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551.
22. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, et al. (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678.
23. Hassan R, Bera T, Pastan I, (2004) Mesothelin. Clinical cancer research 10: 3937.
24. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, et al. (1999) Soluble member (s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proceedings of the National Academy of Sciences 96: 11531-11536.
25. Choi JH, Choi KC, Auersperg N, Leung PCK, (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. Journal of Clinical Endocrinology & Metabolism 89: 5508-5516.
26. Ramakrishna V, Negri DRM, Brusic V, Fontanelli R, Canevari S, et al. (1997) Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA'Äêrestricted cytotoxic T cells. International journal of cancer 73: 143-150.
27. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, et al. (2008) Müllerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers. Gynecologic oncology 108: 141-148.
28. Durrant LG, Pudney VA, Spendlove I, (2011) Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Rev Vaccines 10: 1093-1106.
29. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST, (2012) Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012 973820.